Arcis have developed and launched a CE-IVD approved ultra-rapid DNA & RNA extraction and preservation technology. In under 3 minutes the technology extracts DNA & RNA from virtually any sample and preserves it instantly for downstream amplification and disease detection. RNA in particular is very fragile and degrades quickly but once preserved in the Arcis reagents it is stable for over 30 days at room temperature - allowing much more accurate detection of a disease or pathogen or even of a cancer biomarker. Arcis have shown that fragile cancer biomarkers can be preserved by using the Arcis technology in urine ( a very difficult bodily fluid). In conjunction with a leading UK University and a Prostate Cancer Charity, results have been demonstrated at detecting RNA cancer biomarkers in urine for up to 7 days (usually they instantly degrade and thus cannot be detected). The plan is to continue developing and then launching (in 2021) a home screening prostate cancer test whereby the consumer simply urinates into a pot containing Arcis, and if any fragile cancer biomarkers are present then they are instantly preserved. The consumer send the pot in the post and a screening assay is then performed to detect the preserved biomarkers. This is far more effective than the current PSA blood test, which can be inaccurate. The other area we are seeing great interest - specifically in China - is in rapid pathogen detection in food , plants, soil, animals and also of course in humans (infectious diseases etc). The Arcis Technology is low cost, rapid (under 3 minutes) and requires no special training or lab equipment. So it can be deployed out of the lab and in "point of care" settings. Chinese government ministries and large pathogen testing labs are currently validating the Arcis Technology in their workflows.,Arcis have developed and launched a CE-IVD approved ultra-rapid DNA & RNA extraction and preservation technology. In under 3 minutes the technology extracts DNA & RNA from virtually any sample and preserves it instantly for downstream amplification and disease detection. RNA in particular is very fragile and degrades quickly but once preserved in the Arcis reagents it is stable for over 30 days at room temperature - allowing much more accurate detection of a disease or pathogen or even of a cancer biomarker. Arcis have shown that fragile cancer biomarkers can be preserved by using the Arcis technology in urine ( a very difficult bodily fluid). In conjunction with a leading UK University and a Prostate Cancer Charity, results have been demonstrated at detecting RNA cancer biomarkers in urine for up to 7 days (usually they instantly degrade and thus cannot be detected). The plan is to continue developing and then launching (in 2021) a home screening prostate cancer test whereby the consumer simply urinates into a pot containing Arcis, and if any fragile cancer biomarkers are present then they are instantly preserved. The consumer send the pot in the post and a screening assay is then performed to detect the preserved biomarkers. This is far more effective than the current PSA blood test, which can be inaccurate. The other area we are seeing great interest - specifically in China - is in rapid pathogen detection in food , plants, soil, animals and also of course in humans (infectious diseases etc). The Arcis Technology is low cost, rapid (under 3 minutes) and requires no special training or lab equipment. So it can be deployed out of the lab and in "point of care" settings. Chinese government ministries and large pathogen testing labs are currently validating the Arcis Technology in their workflows.